Navigation Links
Loxapine in Medical News

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...art of that transaction, Alexza licensed to Symphony Allegro its Staccato loxapine program and its Staccato alprazolam program. Since that time, Alexza has...ed certain intellectual property rights to Staccato alprazolam and Staccato loxapine in connection with our Symphony Allegro arrangement and will not receive ma...

Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008

...ide $50 million of funding through Symphony Allegro, an affiliate of Symphony Capital, for additional clinical and nonclinical development of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza continues to be primarily responsible for the development of these three product candidat...
Loxapine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...l established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product c...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

...s a potentially important new drug candidate for treating acute agitation. loxapine is a well established antipsychotic and the Staccato system enables patient...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...resident, Research and Development. "We believe that the ability to provide loxapine via our Staccato technology, thus combining a drug with a well-established ...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...t the patients remained in the clinic. Alexza's original IND for Staccato loxapine was filed with the Division of Neuropharmacological Drug Products of the FD...ducts, or DPP, and the Division of Neurology Products, or DNP. The Staccato loxapine IND was transferred to the DPP, as the AZ-004 development program is for a ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ...e end of September 2008. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marrio...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...er designed to generate and deliver excipient-free loxapine aerosol for deep lung delivery that results in IV-... The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset o...d other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-00...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

...tion annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation N...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

...ient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

...stem with loxapine, a drug belonging to the class of compounds known as antipsychotics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...
Loxapine in Biological Technology

Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ... schizophrenic patients. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...
Other Tags
(Date:9/3/2015)... ... 2015 , ... Global Vision , the world leader in the development ... print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. ... London, booth #F33 , Be the first to get a sneak peek of Intelligent ...
(Date:9/3/2015)... Philadelphia (PRWEB) , ... September ... ... global provider of high-quality patient safety and efficacy endpoint data collection, cloud ... Annual European PRO and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. ...
(Date:9/3/2015)... ... ... “Love in Tokyo” an independent romantic comedy film by Michael Solton was ... will be released on DVD early next year, by Maverick Entertainment. The film stars ... singer/songwriter, and Jason London, lead from “Dazed and Confused.” , “Love in Tokyo” ...
(Date:9/3/2015)... ... , ... When looking at the types of people who have a hard time gaining ... have a weak appetite or those that have a fast metabolism. In order to help ... Gainer gives three tips for slowing down metabolism. , The first thing to do is ...
(Date:9/3/2015)... ... 2015 , ... Doctor Kayode Sotonwa can be counted on time ... on internal medicine keeps patients happy and healthy, something that is important to everyone. ... season, but even more so in the fall, when holiday eating and seasonal illnesses ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
Other Contents